EMA Withdrawn: Airexar Spiromax (salmeterol;fluticasone propionate) — Teva B.V.

View source ↗

Summary

EMA has withdrawn Airexar Spiromax (salmeterol; fluticasone propionate) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Airexar Spiromax (salmeterol; fluticasone propionate)

Snippet

Status: Withdrawn. Therapeutic area: Pulmonary Disease, Chronic Obstructive;Asthma. MAH: Teva B.V.. Decision date: 19/02/2018